Bortezomib Plus Rituximab for EBV+ PTLD

• ClinicalTrials.gov Identifier: NCT01058239
• Recruitment Status: Completed
• First Posted: January 28, 2010
• Results First Posted: February 15, 2018
• Last Update Posted: February 15, 2018
• Sponsor: Massachusetts General Hospital
• Collaborators: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Millennium Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Jeremy Abramson, MD, Massachusetts General Hospital

Study Description

Brief Summary:

Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation. This is usually related to a virus called Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) to treat multiple myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the addition of bortezomib to rituximab treatment can increase the rate of complete remissions and cures of PTLD after organ or stem cell transplant.

Condition or disease	Intervention/treatment	Phase
Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections	Drug: bortezomib; Drug: rituximab	Phase 2

Detailed Description:

• Both rituximab and bortezomib will be given to participants intravenously. Each cycle of treatment will consist of 21 days. Rituximab will be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles. Bortezomib will be given on Days 1, 4, 8 and 11 of every cycle. Participants will receive a maximum of 4 cycles.
• The following study procedures will be performed during each cycle throughout the study: Medical history review; Physical exam; Performance Status; Questionnaire; Blood draws and; PET/CT scans (After cycles 2, 4 and 6 only).
• After Cycle 4, if the study doctor feels the participant has had a complete response to treatment, then they will continue onto the Post-Treatment Surveillance period, which will consist of regular clinic visits over two years.
• However, if the study doctor feels the participant has had a partial response to treatment and that they may benefit from continuing, they will receive an additional two cycles of bortezomib and be given daily tablets of the antiviral drug valganciclovir to help further target EBV.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 7 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)
• Actual Study Start Date: November 2011
• Actual Primary Completion Date: December 2016
• Actual Study Completion Date: November 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Rituximab plus Bortezomib; This is a single arm trial adding the new drug bortezomib to the standard drug rituximab	Drug: bortezomib; Given intravenously on days 1, 4, 8 and 11 of every cycle; Other Name: Velcade; Drug: rituximab; given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles; Other Names: Rituxan; Mabthera

Outcome Measures

Primary Outcome Measures :

1. Overall Response Rate [ Time Frame: 4 months ]

   Overall response rate includes both complete and partial responses assessed by PET/CT following completion of therapy. Response was evaluated using the International Working Group criteria for lymphoma response. The complete list of criteria used to evaluate response is too long to be detailed in the allotted space here, but response is defined more generally as:

   • Complete Response (CR): Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
   • Partial Response (PR): ≥ 50% decrease in the sum of the products of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.

Secondary Outcome Measures :

1. Complete Response Rate [ Time Frame: 4 Months ]

   The number of participants with complete responses as assessed by PET/CT following completion of therapy. Response was evaluated using the International Working Group criteria for lymphoma response.

   Complete Response (CR): Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

2. Six-Month Progression Free Survival [ Time Frame: six months ]

   Percent of participants with progression free survival (alive without disease progression) six months after registration. Progression was evaluated using the International Working Group criteria for lymphoma response.

   > Progressive Disease (PD) or Relapsed Disease (RD):

   1. Appearance of any new lesion > 1.5 cm in any axis during or at end of therapy. Increased Radiolabeled[18F]-2-fluoro-2-deoxy-D-glucose (FDG) uptake in a previously unaffected site will be considered PD/RD only after confirmation by other modalities.
   2. ≥ 50% increase from nadir in the sum of the products of the largest diameters (SPD) of any previously involved node, or in a single involved node, or in the sizes of other lesions.
   3. ≥ 50% increase in the longest diameter of any single previously identified node > 1 cm in its short axis.
   4. PET (positron emission tomography) positive prior to therapy: post-treatment PET should be positive unless lesion is too small to be detected with current PET sys
3. Overall Survival [ Time Frame: 6 months, 1 year ]
   The percent of participants surviving at 6 months and 1 year.
4. Effects of Bortezomib/Rituximab on EBV Quantitative Viral Load [ Time Frame: baseline, 21, 42, 63, 84 days (end of cycles 1, 2, 3, 4) ]
   The Mean epstein barr virus (EBV) viral load at the given time points.
5. Treatment Related Toxicities [ Time Frame: 2 years ]
   The toxicities experienced by participants that were deemed to be related to the study treatment. Data is shown as the number of participants that experienced any grade toxicity that was deemed to be related to treatment. Toxicities were assessed with the use of Common Toxicology Criteria for Adverse Events (CTCAE).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have had a prior solid organ or allogeneic stem cell transplant.
• Patients may be newly-diagnosed or relapsed after prior therapy
• Patients must have histologically confirmed CD20+ B-cell PTLD diagnosed according to WHO criteria. PTLD may be characterized as early lesions, PTLD/polymorphic, PTLD/monomorphic, or PTLD/other, all of which are eligible for this trial. B-cell PTLD must be associated with EBV as demonstrated either by detection of EBV antigens in tumor samples, or by increased EBV quantitative viral load in serum.
• Patients must have measurable disease
• 18 years of age or older
• Estimated life expectancy of > 3 months
• ECOG Performance status of 0, 1, or 2
• Adequate organ and marrow function
• Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.

Exclusion Criteria:

• Patients receiving any other study agents. Patients already on prophylactic doses of ganciclovir or valganciclovir because of a prior history of CMV infection or because of risk factors for CMV infection are eligible for the study and may continue CMV prophylaxis.
• Patients with known brain metastases or central nervous system (CNS) involvement of their lymphoma.
• Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, rituximab, ganciclovir or valgancyclovir.
• Patients with Grade 2 or greater neuropathy within 14 days before enrollment.
• Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• Psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or breastfeeding women
• Individuals with a history of malignancy are ineligible except for those outlined in the protocol
• Known HIV positive individuals
• Active HBV infection may be included only if they are on appropriate anti-hepatitis B therapy and have an undetectable HBV viral load
• Patient has received other investigational drugs within 14 days before enrollment
• Prior bortezomib

Contacts and Locations

Locations

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Sponsors and Collaborators

Massachusetts General Hospital

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Beth Israel Deaconess Medical Center

Millennium Pharmaceuticals, Inc.

Investigators

• Principal Investigator: Jeremy Abramson, MD; Massachusetts General Hospital

More Information

• Responsible Party: Jeremy Abramson, MD, Director, Lymphoma Program, Massachusetts General Hospital
• ClinicalTrials.gov Identifier: NCT01058239
• Other Study ID Numbers: 09-346; X05289 ( Other Identifier: Millennium )
• First Posted: January 28, 2010
• Results First Posted: February 15, 2018
• Last Update Posted: February 15, 2018
• Last Verified: January 2018

Keywords provided by Jeremy Abramson, MD, Massachusetts General Hospital:

bortezomib; rituximab; PTLD; EBV; transplantation

Additional relevant MeSH terms:

Epstein-Barr Virus Infections; Lymphoproliferative Disorders; Virus Diseases; Infections; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Herpesviridae Infections; DNA Virus Infections; Tumor Virus Infections; Rituximab; Bortezomib; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents